<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38508863</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1326-5377</ISSN><JournalIssue CitedMedium="Internet"><Volume>220</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>The Medical journal of Australia</Title><ISOAbbreviation>Med J Aust</ISOAbbreviation></Journal><ArticleTitle>Long COVID in a highly vaccinated but largely unexposed Australian population following the 2022 SARS-CoV-2 Omicron wave: a cross-sectional survey.</ArticleTitle><Pagination><StartPage>323</StartPage><EndPage>330</EndPage><MedlinePgn>323-330</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5694/mja2.52256</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To estimate the prevalence of long COVID among Western Australian adults, a highly vaccinated population whose first major exposure to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was during the 2022 Omicron wave, and to assess its impact on health service use and return to work or study.</AbstractText><AbstractText Label="STUDY DESIGN">Follow-up survey (completed online or by telephone).</AbstractText><AbstractText Label="SETTING, PARTICIPANTS">Adult Western Australians surveyed 90 days after positive SARS-CoV-2 test results (polymerase chain reaction or rapid antigen testing) during 16 July - 3 August 2022 who had consented to follow-up contact for research purposes.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Proportion of respondents with long COVID (ie, reporting new or ongoing symptoms or health problems, 90 days after positive SARS-CoV-2 test result); proportion with long COVID who sought health care for long COVID-related symptoms two to three months after infection; proportion who reported not fully returning to previous work or study because of long COVID-related symptoms.</AbstractText><AbstractText Label="RESULTS">Of the 70&#x2009;876 adults with reported SARS-CoV-2 infections, 24&#x2009;024 consented to contact (33.9%); after exclusions, 22&#x2009;744 people were invited to complete the survey, of whom 11&#x2009;697 (51.4%) provided complete responses. Our case definition for long COVID was satisfied by 2130 respondents (18.2%). The risk of long COVID was greater for women (v men: adjusted risk ratio [aRR], 1.5; 95% confidence interval [CI], 1.4-1.6) and for people aged 50-69 years (v 18-29 years: aRR, 1.6; 95% CI, 1.4-1.9) or with pre-existing health conditions (aRR, 1.5; 95% CI, 1.4-1.7), as well as for people who had received two or fewer COVID-19 vaccine doses (v four or more: aRR, 1.4; 95% CI, 1.2-1.8) or three doses (aRR, 1.3; 95% CI, 1.1-1.5). The symptoms most frequently reported by people with long COVID were fatigue (1504, 70.6%) and concentration difficulties (1267, 59.5%). In the month preceding the survey, 814 people had consulted general practitioners (38.2%) and 34 reported being hospitalised (1.6%) with long COVID. Of 1779 respondents with long COVID who had worked or studied before the infection, 318 reported reducing or discontinuing this activity (17.8%).</AbstractText><AbstractText Label="CONCLUSION">Ninety days after infection with the Omicron SARS-CoV-2 variant, 18.2% of survey respondents reported symptoms consistent with long COVID, of whom 38.7% (7.1% of all survey respondents) sought health care for related health concerns two to three months after the acute infection.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors. Medical Journal of Australia published by John Wiley &amp; Sons Australia, Ltd on behalf of AMPCo Pty Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Woldegiorgis</LastName><ForeName>Mulu</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6489-980X</Identifier><AffiliationInfo><Affiliation>Communicable Disease Control Directorate, Western Australia Department of Health, Perth, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cadby</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Communicable Disease Control Directorate, Western Australia Department of Health, Perth, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngeh</LastName><ForeName>Sera</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Communicable Disease Control Directorate, Western Australia Department of Health, Perth, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korda</LastName><ForeName>Rosemary J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armstrong</LastName><ForeName>Paul K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Communicable Disease Control Directorate, Western Australia Department of Health, Perth, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maticevic</LastName><ForeName>Jelena</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Communicable Disease Control Directorate, Western Australia Department of Health, Perth, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Communicable Disease Control Directorate, Western Australia Department of Health, Perth, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jardine</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Environmental Health Directorate, Western Australia Department of Health, Perth, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bloomfield</LastName><ForeName>Lauren E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Communicable Disease Control Directorate, Western Australia Department of Health, Perth, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Notre Dame Australia, Fremantle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Effler</LastName><ForeName>Paul V</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>Communicable Disease Control Directorate, Western Australia Department of Health, Perth, WA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Med J Aust</MedlineTA><NlmUniqueID>0400714</NlmUniqueID><ISSNLinking>0025-729X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName><SupplMeshName Type="Population" UI="C000726213">Australians</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094861" MajorTopicYN="Y">Australasian People</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">Health services</Keyword><Keyword MajorTopicYN="N">Models, statistical</Keyword><Keyword MajorTopicYN="N">Population health</Keyword><Keyword MajorTopicYN="N">Prevention and control</Keyword><Keyword MajorTopicYN="N">Public health</Keyword><Keyword MajorTopicYN="N">Public policy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>21</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>20</Day><Hour>22</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38508863</ArticleId><ArticleId IdType="doi">10.5694/mja2.52256</ArticleId></ArticleIdList><ReferenceList><Title/><Reference><Citation>Al&#x2010;Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS&#x2010;CoV&#x2010;2 infection. Nat Med 2022; 28: 1461&#x2010;1467.</Citation></Reference><Reference><Citation>Alwan NA, Johnson L. Defining long COVID: going back to the start. Med 2021; 2: 501&#x2010;504.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Long COVID or post&#x2010;COVID conditions. Updated 20 July 2023. https://www.cdc.gov/coronavirus/2019&#x2010;ncov/long&#x2010;term&#x2010;effects/index.html (viewed June 2022).</Citation></Reference><Reference><Citation>Crook H, Raza S, Nowell J, et&#xa0;al. Long covid&#x2010;mechanisms, risk factors, and management. BMJ 2021; 374: n1648.</Citation></Reference><Reference><Citation>Salamanna F, Veronesi F, Martini L, et&#xa0;al. Post&#x2010;COVID&#x2010;19 syndrome: the persistent symptoms at the post&#x2010;viral stage of the disease. A systematic review of the current data. Front Med (Lausanne) 2021; 8: 653516.</Citation></Reference><Reference><Citation>Kingstone T, Taylor AK, O'Donnell CA, et&#xa0;al. Finding the &#x201c;right&#x201d; GP: a qualitative study of the experiences of people with long&#x2010;COVID. BJGP Open 2020; 4: bjgpopen20X101143.</Citation></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et&#xa0;al. Attributes and predictors of long COVID. Nat Med 2021; 27: 626&#x2010;631.</Citation></Reference><Reference><Citation>World Health Organization. A clinical case definition of post COVID&#x2010;19 condition by a Delphi consensus, 6 October 2021. https://www.who.int/publications/i/item/WHO&#x2010;2019&#x2010;nCoV&#x2010;Post_COVID&#x2010;19_condition&#x2010;Clinical_case_definition&#x2010;2021.1 (viewed June 2022).</Citation></Reference><Reference><Citation>World Health Organization. Post COVID&#x2010;19 condition (long COVID). 7 Dec 2022. https://www.who.int/europe/news&#x2010;room/fact&#x2010;sheets/item/post&#x2010;covid&#x2010;19&#x2010;condition (viewed Oct 2023).</Citation></Reference><Reference><Citation>Bloomfield LE, Ngeh S, Cadby G, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 vaccine effectiveness against omicron variant in infection&#x2010;naive population, Australia, 2022. Emerg Infect Dis 2023; 29: 1162&#x2010;1172.</Citation></Reference><Reference><Citation>Katella K. Omicron, delta, alpha, and more: what to know about the coronavirus variants. Yale Medicine, 1 Sept 2023. https://www.yalemedicine.org/news/covid&#x2010;19&#x2010;variants&#x2010;of&#x2010;concern&#x2010;omicron (viewed Mar 2023).</Citation></Reference><Reference><Citation>Western Australia Department of Health. Assessing the risk of long COVID in Western Australia (RGS0000005516), version 2 [unpublished research protocol]. 28 Sept 2022.</Citation></Reference><Reference><Citation>Hughes SE, Haroon S, Subramanian, et&#xa0;al. Development and validation of the symptom burden questionnaire for long covid (SBQ&#x2010;LC): Rasch analysis. BMJ 2022; 377: e070230.</Citation></Reference><Reference><Citation>Blevins C, Mullen L. Jane, John&#x2026; Leslie? A historical method for algorithmic gender prediction. DHQ 2015; http://www.digitalhumanities.org/dhq/vol/9/3/000223/000223.html (viewed Oct 2023).</Citation></Reference><Reference><Citation>Ayoubkhani D, Pawelek P. Prevalence of ongoing symptoms following coronavirus (COVID&#x2010;19) infection in the UK: 1 April 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021 (viewed Feb 2024).</Citation></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et&#xa0;al. Symptoms and risk factors for long COVID in non&#x2010;hospitalized adults. Nat Med 2022; 28: 1706&#x2010;1714.</Citation></Reference><Reference><Citation>Thompson EJ, Williams DM, Walker AJ, et&#xa0;al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun 2022; 13: 3528.</Citation></Reference><Reference><Citation>Government of Canada. COVID&#x2010;19: Longer&#x2010;term symptoms among Canadian adults; second report. Associations between longer&#x2010;term symptoms after COVID&#x2010;19 and sociodemographics, health characteristics, period of infection, and vaccination status in Canadian adults, January 2020 to August 2022. Updated 24 Mar 2023. https://health&#x2010;infobase.canada.ca/covid&#x2010;19/post&#x2010;covid&#x2010;condition/spring&#x2010;2023&#x2010;report.html (viewed June 2023).</Citation></Reference><Reference><Citation>Australian Institute of Health and Welfare. Long COVID in Australia: a review of the literature (PHE 318). 16 Dec 2022. https://www.aihw.gov.au/getmedia/9592f439&#x2010;9b96&#x2010;4589&#x2010;a55d&#x2010;6b04e262e5e1/aihw&#x2010;phe&#x2010;318.pdf.aspx?inline=true (viewed May 2023).</Citation></Reference><Reference><Citation>Brown M, Gerrard J, McKinlay L, et&#xa0;al. Ongoing symptoms and functional impairment 12 weeks after testing positive for SARS&#x2010;CoV&#x2010;2 or influenza in Australia: an observational cohort study. BMJ Public Health 2023; 1: e000060.</Citation></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, et&#xa0;al. Risk of long COVID associated with delta versus omicron variants of SARS&#x2010;CoV&#x2010;2. Lancet 2022; 399: 2263&#x2010;2264.</Citation></Reference><Reference><Citation>Menges D, Ballouz T, Anagnostopoulos A, et&#xa0;al. Burden of post&#x2010;COVID&#x2010;19 syndrome and implications for healthcare service planning: a population&#x2010;based cohort study. PLoS One 2021; 16: e0254523.</Citation></Reference><Reference><Citation>Western Australia Department of Health. COVID&#x2010;19 weekly surveillance report: 19 December to 25 December 2022. https://www.health.wa.gov.au/~/media/Corp/Documents/Health&#x2010;for/Infectious&#x2010;disease/COVID19/Weekly&#x2010;surveillance&#x2010;report/COVID&#x2010;19&#x2010;Weekly&#x2010;Surveillance&#x2010;report&#x2010;19&#x2010;December&#x2010;25&#x2010;December&#x2010;2022.pdf (viewed June 2023).</Citation></Reference><Reference><Citation>Fischer K, Reade JJ, Schmal WB. What cannot be cured must be endured: the long&#x2010;lasting effect of a COVID&#x2010;19 infection on workplace productivity. Labour Econ 2022; 79: 102281.</Citation></Reference><Reference><Citation>Kuodi P, Gorelik Y, Zayyad H, et&#xa0;al. Association between BNT162b2 vaccination and reported incidence of post&#x2010;COVID&#x2010;19 symptoms: cross&#x2010;sectional study 2020&#x2013;21, Israel. NPJ Vaccines 2022; 7: 101.</Citation></Reference><Reference><Citation>Walter JK, Davis MM. Who's willing? Characteristics associated with willingness to participate in clinical research. IRB 2016; 38: 15&#x2010;20.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>